Huge demand for weight loss drugs Ozempic and Wegovy continue to drive an incredible performance for Novo Nordisk. The Danish pharmaceutical company raised its full-year profit outlook after quarterly sales surged 24 per cent and net profits soared 28 per cent. However it is facing increased competition from US rival Eli Lilly. Novo Nordisk is now Europe's biggest company with a valuation of over $570bn (£455bn) after it overtook French luxury conglomerate LVMH in September last year. LVMH had held the top

(c) 2024 City A.M., source Newspaper